Nature SciCafe Asia is a series of biotech sessions for investors, entrepreneurs, scientists, government agencies & industry representatives.

It allows attendees to be active players in the development of a strong biotech investment environment in Asia & connects rising stars in biomedical research with global investment communities.


“Nature SciCafe Asia recognises the critical importance of building productive relationships between investors and commercially-oriented scientists in Asia. It creates synergies between scientific, government and investment stakeholders in order to facilitate the commercialisation of life-saving technologies that might otherwise not be realised”

Prof Ivy Ng, Group CEO, SingHealth
Prof Ranga Krishnan, Dean (July 2008 – June 2015), Duke-NUS.

Scientific discoveries and findings made in research laboratories are often not immediately beneficial to patients. It has to undergo years of further studies, tests, clinical trials or commercialisation before it can be applied in the clinical setting – as biomarkers, drugs, treatment modalities or medical devices.

So to boost the translation of research findings into actual care outcomes that will impact patients, began the partnership with Nature Biotechnology and Nature Medicine to host the inaugural Nature SciCafe Asia.

 Jointly organised by Singapore Health Services (SingHealth), Duke-NUS Medical School and Eureka Institute of Translational Medicine – today, the Nature SciCafe Asia has grown to be a series of biotech sessions that aims to build a strong biotech investment community right here in Asia.

“2015 is the first time that the Nature SciCafe Asia has been organised in Asia, and we are proud to be able to host it. We hope that the SciCafé will advance translational research here in Asia, in the same way that it synergises strategic collaborations to further research commercialisation in the US and Europe where it is held regularly”

Prof Salvatore Albani

Jointly organised by:

Supported by:

In association with:

Past Events